Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Evidence of improvement in disease severity

Dig Dis Sci. 1993 Apr;38(4):644-7. doi: 10.1007/BF01316794.


Nineteen consecutive patients with acute pancreatitis were sequentially allocated to treatment with high-dose octreotide (N = 9) or to act as controls (N = 10). All other aspects of treatment were similar and were according to a strict treatment protocol. There was no significant difference between the two groups on admission with regard to recognized criteria of poor prognosis. The octreotide-treated group required significantly less analgesia and after 48 hr developed significantly fewer poor prognostic indicators, including falls in hematocrit of > 10%, in serum albumin to < 32 g/liter, and in serum calcium to < 2.00 mmol/liter. Falls in arterial PO2 to < 10 kPa, in serum albumin of > 20%, and in hemoglobin of > 2 g/dl were also significantly less frequent. There was a trend towards improvement in the octreotide-treated group in every other physiological and radiological indicator of disease severity. High-dose octreotide may reduce the severity of acute pancreatitis.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Combined Modality Therapy
  • Humans
  • Middle Aged
  • Octreotide / administration & dosage*
  • Pancreatitis / blood
  • Pancreatitis / drug therapy*
  • Prognosis
  • Remission Induction
  • Severity of Illness Index


  • Octreotide